These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1979657)

  • 41. An integrated approach to patient management in Parkinson's disease.
    Lieberman A
    Neurol Clin; 1992 May; 10(2):553-65. PubMed ID: 1350053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
    Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
    Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
    Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
    Bowes SG; Dobbs RJ; Henley M; Charlett A; O'Neill CJ; Nicholson PW; Purkiss AG; Weller C; Dobbs SM
    Eur J Clin Pharmacol; 1992; 43(5):483-9. PubMed ID: 1483485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
    Karstaedt PJ; Pincus JH; Coughlin SS
    Arch Neurol; 1991 Apr; 48(4):402-5. PubMed ID: 2012514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
    Hutton JT; Morris JL
    Can J Neurol Sci; 1991 Nov; 18(4):467-71. PubMed ID: 1782612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
    Bulling MT; Wing LM; Burns RJ
    Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
    Coleman RJ; Quinn NP; Traub M; Marsden CD
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
    Ming A; Temlett JA; Fritz VU
    J Intern Med; 1991 Aug; 230(2):113-7. PubMed ID: 1865161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
    Weiner WJ; Factor SA; Sanchez-Ramos JR
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The long-duration action of levodopa may be due to a postsynaptic effect.
    Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.